KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Notes Payables (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Notes Payables for 17 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Notes Payables rose 8.33% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 8.33% year-over-year, with the annual reading at $1.3 million for FY2025, 8.33% up from the prior year.
  • Notes Payables for Q4 2025 was $1.3 million at Bio-Rad Laboratories, roughly flat from $1.3 million in the prior quarter.
  • The five-year high for Notes Payables was $1.7 million in Q3 2021, with the low at $448000.0 in Q3 2022.
  • Average Notes Payables over 5 years is $904400.0, with a median of $511500.0 recorded in 2022.
  • The sharpest move saw Notes Payables crashed 99.59% in 2021, then surged 169.15% in 2025.
  • Over 5 years, Notes Payables stood at $489000.0 in 2021, then fell by 4.91% to $465000.0 in 2022, then increased by 7.53% to $500000.0 in 2023, then surged by 140.0% to $1.2 million in 2024, then grew by 8.33% to $1.3 million in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $1.3 million, $1.3 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.